You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202281 - 202290 of 207712 results
  1. A point of care test for TB antibiotic concentration in blood

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    TuberculosisTBis one of the topcauses of death worldwideTB treatments include combinations of multiple antibiotics and dosage levels over a long period of timeOften the dose must be adjustedLow antibiotic blood concentrations may cause slow responseprolonged infection or treatment failureand the TB strain may acquire drug resistancetoo high and toxicity may be an issueCurrent technologies for meas ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. POC Diagnostic for Gonorrhea and Determination of Antimicrobial Susceptibility

    SBC: Visby Medical, Inc.            Topic: NIAID

    VisbyFormally know as Click Diagnosticshas developed a PCR based rapiddisposablepoint of care test that automatically performs sample processingPCR amplificationand amplicon detectionLeveraging the existing platformClick willfrom a single urogenital sampledetect NG and determine whether the infecting strain is susceptible to three classes of antibioticsciprofloxacincefiximeor a novel antibiotic zo ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb

    SBC: ANTAGEN BIOSCIENCES INC            Topic: NIAID

    HIVthe virus that causes AIDSis one of the world s most serious health challengesAccording to UNAIDSthere were approximatelymillion people worldwide living with HIV AIDS at the end ofThe vast majority of them are in lowto middle income countriesparticularly in sub Saharan AfricaA low cost vaccine broadly neutralizing most strains of HIV is the preferred response to protect the human populationHowe ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Mobile Health Point-of-Care Diagnostics for Tuberculosis

    SBC: B & W TEK INC            Topic: NIAID

    TuberculosisTBkilled an estimatedmillion people in the world inOverof the mortalities associated with this deisease occurred in regions of the world where access to reliable TB testing and other suppotive infrastructure is severely limitedUntil there are pivotal technological innovations in the diagnosis of TB for point of carePOCapplicationthe ambitious goals of the WHO s End TB strategyareductio ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Electrochemical aptasensor for Anti-Tuberculosis antibiotic quantification

    SBC: GUILD ASSOCIATES INC            Topic: NIAID

    Specific AimsIn Phase I of this SBIRwe will complete three specific aimssynthesize stable combination adjuvant formulations that are compatible with an HVLP antigenidentify the combination adjuvant properties that augment the safe and durable immunity to Handdemonstrate the superior protective benefit of the new combination adjuvant over existing adjuvant solutions for pandemic influenza vaccinesI ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine

    SBC: ADJUVANCE TECHNOLOGIES INC.            Topic: NIAID

    Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking aug ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. New Carriers Used as Adjuvants for Controlled HIV Immunogen Delivery into Targeted Antigen Presenting Cells

    SBC: NANOCOMPOSIX, INC.            Topic: NIAID

    Despite the global impacts of HIV on human healthwith an estimatedmillion new cases each year andmillion people living with HIVan effective vaccine has not been developedThere are many challenges for HIV vaccine development including the virus s rapidly changing surface immunogens and the early integration of the virus into the host s genomeTo overcome these challengesa mesoporous silica adjuvant ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Mobile Health Point-of-Care Diaagnostics for Malaria

    SBC: CHROMOLOGIC LLC            Topic: NIAID

    A resurgence of malaria infections has occurred in the USprimarily due to increasing global travelOnly wide spread screenings and treatments of endemic populations can prevent the return of malaria endemicityCurrentlythere is no diagnostic test that meets the need of highly sensitive malaria screening tool for low resource settingsTo address this needChromoLogic proposes to develop the Quick Mag p ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. A Self-Replicating RNA Vaccine Against HIV-1 Delivered Using A Nanoparticle Adjuvant

    SBC: PAI LIFE SCIENCES INC            Topic: NIAID

    An effective vaccine against HIV offers the best chance to stop the global epidemic but remains elusive to dateResearch has primarily focused on subunit monomerice ggpor gpor trimeric antigensthe former approachoften adjuvanted with alumhas failed in clinical trialsNative like trimers mimic the Env spike but are still poorly immunogenic and require elaborate adjuvant screening efforts to potentiat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of VesiVax Adjuvant Formulations for HIV Vaccines

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    This proposal aim to develop a VesiVaxplatform based liposomal vaccine that can co formulate the HIV antigenHIV Env gpAwith various immunotimulatory adjuvant moleculesIAMsThe IAMs that we will formulate with the antigen includeslipidated tucaresolmuramyl tripeptide phosphatidylethanolaminePam CAGmonophosphoryl lipid AdsRNAandcyclic dinucleotidesThe formulations will be evaluated in miceand selecte ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government